GeneDx Reports Strong Q1 2025 Growth and Expansion Plans

Genedx Holdings Corp. ( (WGS) ) has released its Q1 earnings. Here is a breakdown of the information Genedx Holdings Corp. presented to its investors.

GeneDx Holdings Corp., a leader in genomic insights, specializes in exome and genome testing to enhance health outcomes, operating primarily in the healthcare sector.

In its first quarter of 2025, GeneDx reported robust financial performance with revenues reaching $87.1 million, marking a significant 62% year-over-year growth in exome and genome test revenue. The company also announced strategic plans to acquire Fabric Genomics, aiming to broaden its market reach.

Key financial highlights include an adjusted net income of $7.7 million, a stark improvement from the previous year’s adjusted net loss of $8.0 million. The company achieved a 69% adjusted gross margin, up from 61% in the same quarter last year, and reduced operating expenses to 60% of revenues. GeneDx also reported a healthy cash position of $160.2 million.

Strategically, GeneDx is expanding its genomic testing capabilities with the launch of ultraRapid Whole Genome Sequencing and new indications for exome and genome testing, including cerebral palsy and Inborn Errors of Immunity. The company is also enhancing its AI-powered diagnostic tools to streamline genetic analysis.

Looking ahead, GeneDx has raised its revenue guidance for 2025 to between $360 and $375 million, with expectations of continued growth in exome/genome volume and revenue by at least 30%. The company remains focused on sustaining profitability and expanding its market presence through strategic acquisitions and innovative product offerings.